Glycopyrronium Bromide And Neostigmine Metilsulfate Mercurypharm (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glycopyrronium bromide and neostigmine methylsulfate injection is indicated for peri‑operative management of secretions and for reversal of non‑depolarizing neuromuscular blockade.

• Reduce salivary, bronchial, and gastric secretions during anesthesia.
• Decrease airway secretions to facilitate endotracheal intubation.
• Reverse residual neuromuscular blockade after surgery when spontaneous recovery is insufficient.
• Support rapid emergence from general anesthesia by restoring muscle strength.
• May be used as an adjunct in patients at risk of aspiration due to excessive secretions.
• Facilitate postoperative recovery by minimizing secretions that can impair ventilation.

The safety profile of the glycopyrronium bromide and neostigmine methylsulfate combination reflects the pharmacology of its two components, with anticholinergic effects from glycopyrronium and cholinesterase inhibition from neostigmine. Most adverse events are mild and transient, but clinicians should remain vigilant for less common but potentially serious reactions.

Common

• Dry mouth due to reduced salivary secretion.
• Transient facial flushing or warmth.
• Mild tachycardia, usually self‑limiting.
• Nausea or mild gastrointestinal discomfort, often short‑lived.

Serious

• Bradycardia or severe cardiac arrhythmia requiring monitoring.
• Bronchospasm or respiratory distress, especially in patients with reactive airways.
• Excessive muscarinic blockade causing urinary retention or ileus.
• Prolonged neuromuscular weakness that may delay recovery of muscle strength.

When using glycopyrronium bromide and neostigmine methylsulfate, several precautionary measures should be observed to ensure patient safety and optimal therapeutic effect.

• Assess baseline cardiac function; avoid use in patients with uncontrolled arrhythmias.
• Monitor heart rate and blood pressure during and after administration.
• Use caution in patients with asthma, COPD, or other reactive airway diseases.
• Evaluate renal and hepatic function, as impaired clearance may increase drug exposure.
• Adjust dose or avoid in patients with known hypersensitivity to anticholinergic or cholinesterase‑inhibitor agents.
• Ensure adequate ventilation and oxygenation, especially when reversing neuromuscular blockade.
• Document timing of administration relative to other anesthetic agents.

Glycopyrronium bromide and neostigmine methylsulfate may interact with other medications administered during anesthesia; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use of other anticholinergic agents (e.g., atropine, scopolamine) that may exacerbate dry‑mouth or tachycardia.
• Potent cholinesterase inhibitors (e.g., pyridostigmine) that could intensify neuromuscular effects.
• Beta‑blockers or calcium‑channel blockers that may compound bradycardic effects when combined with glycopyrronium.

Use with caution

• Inhaled bronchodilators or beta‑agonists, as combined respiratory effects need monitoring.
• Opioid analgesics, which may mask signs of respiratory depression.
• Anesthetic agents that also affect heart rate or secretions, requiring dose adjustments.
• Neuromuscular monitoring agents, as overlapping effects may alter the assessment of blockade reversal.